A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.

Jin LiZhiqiang WangHaijun ZhongYifu HeChen ZhangZuoxing NiuShujun YangTao ZhangLiangjun ZhuYongqian ShuYong GaoJianjun PengYan SongJian LiYing YuanHaibo ZhangGengsheng YuYunqi HuaJianjun XiaoJianfei FuYulong ZhengHua XueXian LuoMing ShiWeiguo SuShu-Kui Qin

Published in: The oncologist (2024)

The safety profile of fruquintinib in the real world was generally consistent with that in clinical studies, and the incidence of TEAEs was numerically lower than known VEGF/VEGFR inhibitor-related AEs. Fruquintinib exhibited manageable safety and tolerability in Chinese patients in the real-world setting.

Keyphrases

clinical practice
vascular endothelial growth factor
risk factors
endothelial cells
randomized controlled trial